Novel technologies for understanding the repertoire of tumour infiltrating T cells in cancer

Targeting AFP in hepatocellular cancer

Combination of viroimmunotherapy with checkpoint inhibitors

Is PD-L1 really a predictive biomarker?

Patient perspective on immunotherapy and the ITOC-3 conference

Hypoxia and its impact on the immune system

Reprogramming the cancer microenvironment with vaccine-based therapy

T cells expressing two additional receptors (TETARs) for the use in a multiple- hit immunotherapy

Biomarkers in t-cell therapy trials

Immunotherapy and personalised medicine in review

Rationale for combining immunotherapy with chemotherapy

Editor's Choice for March 2016